Educate Girls Among the World’s 100 Most Inspiring Innovations in K12 Education
13.11.2020 14:34:00 EET | Business Wire | Press release
Educate Girls, a nonprofit organisation working for girls’ education in the remotest villages of India, has announced its selection in HundrED 2021 Global Collection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005344/en/
Girls studying in a remote classroom in rural India, with the help of remedial learning curriculum of Educate Girls (Photo: Business Wire)
Internationally renowned education non-profit HundrED’s annual Global Collection highlights 100 of the most impactful innovations in K12 education from around the world. Educate Girls’ innovation was reviewed by 150 Academy Members consisting of academics, educators, innovators, funders and leaders from over 50 countries. “This innovation has demonstrated a very high degree of impact and scalability that matches really well with the audacious goals they have set,” marked a HundrED Academy Member.
“I’m thankful to HundrED for recognising the urgency of this cause, especially in the midst of this global disruption of education. Using advanced analytics and community mobilization to identify, enrol and retain girls in schools from the most marginalized communities in rural India, we aim to empower over a million girls to access quality education,” says Safeena Husain, Founder of #EducateGirls.
Since 2007, Educate Girls has enroled over 750,000 girls in schools, improving learning outcomes for over 1.3 million children. They are well-known for the world’s first Development Impact Bond and becoming the first Audacious Project in Asia.
About Educate Girls:
Educate Girls is a nonprofit organization that mobilizes communities for girls’ education in India’s rural and educationally backward areas. Working in partnership with the Government, Educate Girls operates in 18,000 villages of Rajasthan, Madhya Pradesh and Uttar Pradesh. By engaging with a huge base of community volunteers, Educate Girls helps to identify, enrol, retain out-of-school girls and improve foundational skills in literacy and numeracy for all children. More on www.EducateGirls.ngo
About HundrED:
A Finland-based global not for profit, HundrED discovers, researches, and shares inspiring innovations in K12 education. HundrED’s goal is to help improve education and foster a movement through encouraging valuable, impactful & scalable innovations to spread, mindful of context, across the world. Since 2016, HundrED has been conducting rigorous research on all continents and selecting 100 inspiring innovations annually. All of the insights and selected innovations are documented, packaged, and shared for free with educators around the world to easily implement. More on www.hundred.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201113005344/en/
Contact information
Educate Girls
Sumedha Mahorey
+919820192152
Sumedha.Mahorey@EducateGirls.ngo
HundrED
MariahoMara@hundred.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom